Yang et al., Aviscumine (ME-503) suppresses the growth of melanoma by potentially targeting c-Myc pathway, Cancer Res 79 (13 Suppl): 1861 (2019)<\/p>\n
U. Trefzer et al., Aviscumine (ME-503) – Skin Reaction as significant Factor for its Efficacy – Expanded Evaluation of the Results from the Phase II Trial NCT00658437 in Patients with Unresectable stage IV Metastatic Melanoma, Immunother Open Acc 3: 135-139 (2017)<\/p>\n
S. Sch\u00f6tterl et al., Viscumins functionally modulate cell motility-associated gene expression, Int. J. Oncology 50: 684-696 (2017)<\/p>\n
P. Mohr et al., Aviscumine (ME-503), a plant protein with a novel mode of action, shows clinical activity in unresectable stage IV metastatic melanoma: data from a phase II trial, Cancer Res 76 (14 Suppl): Abstract nr CT123 (2016)<\/p>\n
U. Trefzer et al., Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study, Journal for Immunotherapy of Cancer 2: 27 (2014)<\/p>\n
H. Zwierzina et al., The preclinical and clinical activity of aviscumine: A potential anticancer drug, European Journal of Cancer 47: 1450-1457 (2011).<\/p>\n
L. Bergmann et al., Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: A study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001), European Journal of Cancer\u00a044<\/strong>: 1657-1662 (2008).<\/p>\n M\u00fcthing et al., Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Ac\u03b12-6Gal\u03b21-4GlcNAc residues are receptors for the anticancer drug rViscumin, FASEB J. 19: 103-105 (2005)<\/p>\n P. Sch\u00f6ffski et al., Weekly 24h infusion of aviscumine (rViscumin): A phase I study in patients with solid tumours, European Journal of Cancer\u00a041<\/strong>: 1431-1438 (2005).<\/p>\n P. Sch\u00f6ffski et al., Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: A study of the European Organization for Research and Treatment of Cancer New Drug Development Group, Annals of Oncology\u00a015<\/strong>: 1816-1824 (2004).<\/p>\n M\u00fcthing et al., Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally \u03b12-6-sialylated neolacto-series gangliosides, Glycobiology 12<\/strong>: 485\u2013497 (2002)<\/p>","protected":false},"excerpt":{"rendered":" Yang et al., Aviscumine (ME-503) suppresses the growth of melanoma by potentially targeting c-Myc pathway, Cancer Res 79 (13 Suppl): 1861 (2019) U. Trefzer et al., Aviscumine (ME-503) – Skin Reaction as significant Factor for its Efficacy – Expanded Evaluation of the Results from the Phase II Trial NCT00658437 in Patients with Unresectable stage IV Metastatic Melanoma, Immunother Open Acc 3: 135-139 (2017) S. Sch\u00f6tterl et al., Viscumins functionally modulate cell motility-associated gene expression, Int. J. Oncology 50: 684-696 (2017) P. Mohr et al., Aviscumine (ME-503), a plant protein with a novel mode of action, shows clinical activity in unresectable stage IV metastatic melanoma: data from a phase II trial, Cancer Res 76 (14 Suppl): Abstract nr CT123 (2016) U. […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-63","page","type-page","status-publish","hentry"],"yoast_head":"\n